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Abstract
Objective To determine the best predictor for the response to
and survival with transarterial radioembolisation (RE) with
90yttrium microspheres in patients with liver metastases.
Methods Forty consecutive patients with liver metastases un-
dergoing RE were evaluated with multiphase CT, perfusion
CT and 99mTc-MAA SPECT. Arterial perfusion (AP) from
perfusion CT, HU values from the arterial (aHU) and portal
venous phase (pvHU) CT, and 99mTc-MAA uptake ratio of
metastases were determined. Morphologic response was eval-
uated after 4 months and available in 30 patients. One-year
survival was calculated with Kaplan-Meier curves.
Results We found significant differences between responders
and non-responders for AP (P<0.001) and aHU (P=0.001) of
metastases, while no differences were found for pvHU (P=
0.07) and the 99mTc-MAA uptake ratio (P=0.40). AP had a
significantly higher specificity than aHU (P=0.003) for deter-
mining responders to RE. Patients with an AP >20 ml/100 ml/
min had a significantly (P=0.01) higher 1-year survival,
whereas an aHU value >55 HU did not discriminate survival
(P=0.12). The Cox proportional hazard model revealed AP as
the only significant (P=0.02) independent predictor of
survival.
Conclusion Compared to arterial and portal venous enhance-
ment and the 99mTc-MAA uptake ratio of liver metastases, the
AP from perfusion CT is the best predictor of morphologic
response to and 1-year survival with RE.
Key Points
• Perfusion CT allows for calculation of the liver arterial
perfusion.
• Arterial perfusion of liver metastases differs between re-
sponders and non-responders to RE.
• Arterial perfusion can be used to select patients responding
to RE.
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Introduction
Transarterial radioembolisation (RE) using 90Y-microspheres
has proven to be a valuable option for patients with
unresectable metastatic liver disease [1–3]. The rationale for
RE is that liver neoplasms mainly have an arterial blood
supply as opposed to healthy liver tissue, which is predomi-
nantly supplied by the portal vein [4]. It has been demonstrat-
ed in explanted livers that 90Y-microspheres mainly accumu-
late in arterially perfused areas of tumours and not in healthy
liver parenchyma [5, 6].
Given that previous studies reported mixed response and
survival rates for RE [7, 8], it is crucial to select patients who
will likely respond to therapy. Some recent studies aimed at
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patient selection based on a semiquantitative assessment of
vascularity using multiphase computed tomography (CT) and
catheter angiography, but did not reveal a correlation between
tumour vascularity and treatment success [9–11]. This has
been explained by the fact that subjective definitions of
hypo- and hypervascularity do not necessarily reflect tumour
histology and angiogenesis [10]. Another such effort involved
measuring the uptake of 99mTc-macroaggregated albumin
(99mTc-MAA) in liver metastases using single-photon emis-
sion CT (SPECT) [12]. However, no relationship was found
between the pattern and extent of 99mTc-MAA uptake in liver
metastases and morphologic tumour response after RE in that
study [12].
A recent preliminary study employing perfusion CT de-
scribed the discriminatory power of the parameter of arterial
perfusion (AP) of liver metastases for distinguishing patients
respondingmorphologically and having a higher survival with
RE than those who did not respond to therapy [13]. However,
the authors addressed only perfusion CT and did not include
other potentially differentiating parameters and modalities in
that study.
The purpose of our study was to determine prospectively,
in patients with liver metastases, the best predictor for re-
sponse to and survival with RE comparing attenuation mea-
surements from arterial and portal venous phase CT, perfusion
CT and the accumulation of 99mTc-MAA particles using
SPECT.
Material and methods
This prospective study had local ethics committee approval.
All patients gave written informed consent.
Study design and patient population
Between November 2010 and June 2012, a total of 58
consecutive patients who planned to undergo treatment
planning catheter angiography and subsequent RE be-
cause of otherwise therapy-refractory metastatic liver dis-
ease were screened for study inclusion (Fig. 1). Follow-
up of patients extended to March 2013. Exclusion criteria
for CT perfusion included a history of hypersensitivity to
iodinated contrast medium (n=0) and nephropathy (esti-
mated glomerular filtration rate <30 ml/min, n=2). Thus,
perfusion CT was performed in 56 patients (30 males,
mean age 64±12 years, range 34–81; 26 females, mean
age 62±11 years, range 39– 82).
Of these 56 patients, 16 were excluded from the study since
no RE was performed based on the results from treatment
planning catheter angiography, including variations in liver
artery anatomy [n=9, this included a measured liver-lung
shunt of over 20 % (n=2), extrahepatic arterial tumour supply
(n=3), inaccessible hepatic artery, e.g., obliterated truncus
coeliacus (n=3) and any liver-intestinal shunt (n=1)] or rap-
idly deteriorating health (n=7). Thus, the final study cohort
comprised 40 patients (22 males, mean age, 64±11 years,
range, 35-81 years; 18 females, mean age 60±12 years, range,
39–79 years, Table 1). All 40 patients underwent CT and
treatment planning catheter angiography including the appli-
cation of 99mTc-MAA and SPECT. Of these 40 patients, 33
(83 %) had multiple metastases in the liver, and 18 (45 %) had
extrahepatic metastatic disease.
RE was performed on average 20 days after treatment
planning catheter angiography. RE was performed as salvage
therapy, and no further treatment was performed within the
study period.
Perfusion computed tomography
All patients were examined using a 128-slice dual-source CT
system (Somatom Definition Flash, Siemens Healthcare,
Forchheim, Germany). The liver contours were identified on
the topogram, and an image volume of 14.8 cm in the z-axis
was placed to cover the majority of the liver. This z-axis
coverage was chosen as a good trade-off between the spatial
and temporal resolution, as well as radiation dose [14]. For
each patient, 50 ml of iopromide (Ultravist 370, 370 mg
iodine/ml, Bayer Schering Pharma, Berlin, Germany) was
injected in an antecubital vein at a flow rate of 5 ml/s followed
by 50 ml of saline solution at the same flow rate. Five
seconds after the contrast material injection, 12 spiral
acquisitions covering the liver were obtained in the
four-dimensional spiral mode with variable pitch from
0 to 0.75. The 5-s delay was chosen to ensure contrast
media-free acquisitions as well as to ensure the arterial
peak was included during the scan time [15]. Images
were acquired with a 1.5-s examination time within a 3-
s cycle time (examination time 35 s). This examination
duration was chosen in order to include both the arterial
liver perfusion and peak of splenic perfusion. Additional
imaging parameters were: 100-kVp tube voltage, 150-
mAs tube current-time product and 128×0.6-mm slice
collimation using the z-flying focal spot. The estimated
effective radiation dose of this protocol was 18 mSv, as
calculated by multiplication of the dose-length product
with the conversion factor for the abdomen (16 μSv/
mGycm) [16]. Patients were instructed to hold their
breath for the entire duration of the examination or to
resume shallow breathing if breath holding was no
longer possible.
CT perfusion images were reconstructed with a slice thick-
ness of 4 mm (increment 3 mm), using a medium smooth
tissue convolution kernel (B20f). All images were transferred
to an external workstation (Multi-Modality Workplace,
Siemens Healthcare) for further analysis.
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Treatment planning catheter angiography and MAA
application
Treatment planning catheter angiography was performed by
one interventional radiologist (18 years of experience in inter-
ventional radiology), who first embolised all branches of the
common hepatic artery that did not supply the liver. In con-
cordance with current recommendations, this was done to
prevent misplacement of 90Y-microspheres in non-hepatic
parenchyma [17]. Then, 180 MBq of 99mTc-MAA was
injected into the hepatic artery or the planned liver
lobe/segment respectively, using a microcatheter. To evaluate
the presence of liver-lung shunting, the shunt fraction was
calculated using planar scintigraphy and SPECT.
99mTc-MAA SPECT
Immediately after 99mTc-MAA application, SPECT was per-
formed on a dual-head gamma camera with an integrated CT
scanner (Infinia Hawkeye, GE Healthcare). For shunt
calculation, images for a planar anterior and posterior whole-
body scintigraphy were acquired. SPECT imaging was
centred on the liver with imaging parameters as follows: peak
140 keV, ±7.5 %, 180°; 3° view angle, matrix 128×128, field
of view 40 cm, 30 s per image, m-mode, zoom 1.0 and low-
energy high-resolution collimator. Reconstruction was per-
formed using the ordered-subsets expectation maximisation
algorithm. CT imaging parameters included 140 kV, 25 mAs,
matrix 256×256, with a 10-mm slice thickness. Soft-tissue
attenuation of the reconstructed 99mTc-MAA SPECT images
was performed. 99mTc-MAA SPECT images were transferred
to a workstation with dedicated software (PMOD, version 3.3,
PMOD Technologies Ltd., Zurich, Switzerland) installed.
Transarterial radioembolisation
On average 20 days (range, 14–24 days) after treatment plan-
ning catheter angiography and 99mTc-MAA SPECT, RE was
performed using 90Y-microspheres (SIR-spheres®, Sirtex Med-
ical Ltd., Lane Cove, Australia) by the same interventional
Fig. 1 Study flow chart depicting the enrolment and inclusion criteria
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radiologist mentioned above in combination with a nuclear
medicine physician (with 5 years of experience in nuclear
oncology). The body surface area method [18] was used to
calculate the dose applied. 90Y-microspheres were administered
in one session to the right lobe (n=14), the left lobe (n=8), the
whole liver (n=17) or spread over two sessions (n=1). Two
sessions at a 2-week interval were deemed necessary because of
the increased toxicity from radioembolisation in heavily
pretreated patients [19]. The time interval between the two
sessions was 2 weeks.
Evaluation of short-term morphologic treatment response
To evaluate the morphologic response of the liver lesions to
RE, the change in lesion size between baseline CT images and
morphologic follow-up images was calculated. The last image
set acquired during the perfusion CT served as the baseline
images. Version 1.1 of the Response Evaluation Criteria in
Solid Tumours (RECIST) was used to classify the response in
the liver [20]. Commercial ly available software
(mintLesion™, version 2.04, Heidelberg, Germany) was
employed to document the measurements. One reader (with
2 years of experience in radiology), who was blinded to the
perfusion CT analyses and patients’ survival, measured all
lesions in the liver on baseline and follow-up images from
the 4-month CT after RE and classified up to two target
lesions, while all other lesions were classified as non-target
lesions. The total lesion diameter of all liver metastases was
calculated and noted as a surrogate for the extension of the
liver tumour load. Additionally, the software classified the
target response, according to RECIST 1.1, into complete
response, partial response, stable disease and progressive dis-
ease. We categorised patients with complete and partial re-
sponse as responders and patients with stable disease and
progressive disease as non-responders, as previously de-
scribed [20–22].
Arterial and portal venous phase CT evaluation
From the 12 spiral CT acquisitions of the perfusion CT we
individually selected the image acquired 12 s after the contrast
in the abdominal aorta exceeded 100 Hounsfield units (HU),
representing the late arterial phase of enhancement [23]. This
single arterial phase was extracted from the multiphase perfu-
sion CT data sets and was presented on an external worksta-
tion to two readers (with 3 and 2 years of experience in
radiology). Readers were presented with the baseline CTslices
with the target lesions delineated and manually drew regions
of interest (ROI) of the corresponding lesions and noted the
corresponding arterial HU (aHU). If there was more than one
target lesion, the mean aHU value of lesions was calculated.
Previously performed, clinically indicated portal venous
CTs were available for 14 of the 40 (35%) patients, performed
at a mean time interval of 27 days (range 14–41 days) prior to
perfusion CT. Similar to the readout of arterial phase CT
images, the baseline CT slices with the target lesions delineat-
ed were presented to the two readers, who manually drew
ROIs of the corresponding lesions and noted the correspond-
ing portal venous HU values (pvHU). If there was more than
one target lesion, the mean pvHU value of lesions was calcu-
lated. The time interval between the readout of arterial phase
and portal venous phase CT images was 4 weeks to avoid
recall bias.
CT perfusion evaluation
Quantitative analysis of CT perfusion data was performed
using commercially available software (Syngo Volume
Table 1 Patient demographics
Sex
Male 22
Female 18
Mean age ± SD (range) 62±12 (35-81)
Diagnosis
Colorectal cancer 20
Adenocarcinoma of the pancreas 4
Breast cancer 4
Adenocarcinoma of the cardia 3
Non-small cell lung cancer 2
Uveal melanoma 2
Renal cell carcinoma 1
Prostate cancer 1
Squamous cell carcinoma of the oesophagous 1
Leiomyosarcoma of the uterus 1
Meningeal haemangiopericytoma 1
Previous treatment
Chemotherapy 33
Liver surgery 10
Radiofrequency ablation 1
Lesions in the liver
Single 6
Multiple 34
Extrahepatic metastases 18
Lobe treated
Whole liver 17
Right liver lobe 14
Left liver lobe 8
Whole liver over two sessions 1
Mean dose applied for RE (GBq) (range) 1.5±0.4 (0.8, 2.8)
Mean time for follow-up in days1 (range) 115±48 (54-312)
1 Of the 30 patients in whom follow-up imaging was available
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Perfusion CT Body, Siemens Healthcare). First, an integrated
motion correction algorithm using a non-rigid deformable
registration technique for anatomic alignment was applied
[24]. Then, a volume of interest (VOI) was drawn around
the entire liver, excluding the hepatic hilum and inferior vena
cava. The peak arterial and peak portal venous enhancement
were measured in regions of interest (ROIs) placed in the
abdominal aorta and the portal vein. A region of interest
(ROI) was drawn in the spleen for separation of arterial and
portal venous phases [25], using the time of maximum en-
hancement within the ROI in the spleen. The maximum slope
of each voxel time-attenuation curve was determined sepa-
rately before and after the separation time point and was
divided by the peak arterial and peak portal venous enhance-
ment. The calculation of hepatic perfusion parameters was
performed according to the method described by Blomley
et al. [26] and Tsushima et al. [27], yielding the arterial
perfusion (AP) in ml/min/100 ml._
Two other independent readers (having 3 and 5 years of
experience in radiology), blinded to the results of short-term
treatment response and patient survival, as well as to the
results from arterial and portal venous CT, were presented
the baseline CT images with the defined target lesions. They
then correlated the target lesions to the arterial perfusion
images and drew VOIs over the corresponding areas (mean
size 40±110 cm3), including the entire lesion while carefully
avoiding the inclusion of larger vessels. The individual arterial
perfusion values of lesions (in ml/100 ml/min) were noted. If
there was more than one target lesion, the mean value of the
lesions was calculated.
99mTc-MAA SPECT evaluation
Two independent readers (with one and two years of experi-
ence in nuclear imaging), blinded to the results fromCTand to
patient survival, were presented the baseline CT images with
the marked target lesions, retraced the matching lesions man-
ually on multiplanar views of the SPECT images and noted
the average 99mTc-MAA uptake of the resulting VOIs. Addi-
tionally, a VOI of defined size (4.5 cm3) was placed in healthy
liver tissue and the average 99mTc-MAA uptake was noted.
The 99mTc-MAA uptake ratio of the target lesions was calcu-
lated as previously shown [12, 28]: 99mTc-MAA uptake
ratio=99mTc-MAA averaged uptake target lesion/99mTc-
MAA averaged uptake normal liver parenchyma. If there
was more than one target lesion the mean value of lesions
was calculated.
Follow-up
Short-term morphologic treatment response was evaluated on
follow-up images 4 months after RE. Morphologic response
was evaluated on CT, which was performed either in house
(n=26) or, for patients not resident in proximity to the authors’
institution, in collaboration (n=14) with the primary care
physician.
Follow-up imaging could not be obtained in ten patients
due to either death before imaging (n=9) or rapidly deterio-
rating health (n=1). These patients therefore were not includ-
ed in the short-term morphologic response analysis, but were
included in the survival analysis (see Fig. 1).
Patients were then followed up, and information on patient
survival was obtained from medical records or telephone
interview up to 1 year after RE.
Statistical analysis
Numeric variables are given as mean ± standard deviation.
Categorical variables are expressed as frequencies and per-
centages. Interreader agreement was evaluated with the
intraclass correlation coefficient (two-way random single
measures) [29].
To determine whether there are significant differences be-
tween responders and non-responders for the parameters
assessed (AP, aHU, pvHU, 99mTc-MAA uptake ratio), the
Mann-Whitney U test was used. In addition, receiver-
operating characteristic (ROC) curves were plotted for the
parameters’ ability to discriminate responders from non-
responders and the area under the curve (AUC) was calculat-
ed. For parameters showing a significant discriminative pow-
er, a cutoff value yielding the same sensitivity was chosen and
the corresponding specificities were compared using the
McNemar test.
To evaluate survival Kaplan-Meier curves were plotted,
and survival between groups was compared with the log-
rank test. To determine parameters significantly influencing
survival, Cox proportional hazard univariate and bivariate
regression analysis was employed. Variables included in the
analysis were: the AP, aHU, pvHU, 99mTc-MAA uptake ratio,
total diameter of all lesions, underlying primary disease, pres-
ence of extrahepatic metastatic disease, total number of liver
metastases, dose applied and pretreatment with chemotherapy.
Commercially available software was used for statistical
analyses (IBM SPSS Statistics, release 20.0, SPSS Inc., Chi-
cago, IL). Statistical significance was inferred at a P-value
below 0.05.
Results
Interreader agreement was high for all parameters (AP:
ICC=0.972, 95 % CI: 0.952-0.983; aHU: ICC=0.988,
95 % CI: 0.977 -0.994; pvHU: 0.965, 95 % CI: 0.877 -
0.981; 99mTc-MAA uptake ratio, ICC=0.825, 95 % CI:
0.657-0.911). Therefore, the values of one reader were
taken for further analysis.
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Follow-up imaging was available in 30 of the 40 patients
(75 %), of whom 19 were classified as non-responders and 11
as responders. Ten patients died prior to follow-up imaging
because of progressive metastatic disease.
Prediction of short-term morphologic response
We found significant (P<0.001) differences between re-
sponders and non-responders for AP with a mean value of
12±6 ml/100 ml/min for non-responders and 38±15 ml/
100 ml/min for responders (Fig. 2a). There was also a signif-
icant (P=0.001) difference in the aHU with a mean HU
number of 52±13 HU for non-responders and 80±24 HU
for responders (Fig. 2b).There was no significant difference
for pvHU values (60±17 HU vs. 82±20 HU, P=0.07)
(Fig. 2c) and for the 99mTc-MAA uptake ratio between re-
sponders and non-responders (5.0±2.9 vs. 4.7±5.6, P=0.40)
(Fig. 2d, Table 2). Representative examples of responders and
non-responders are shown in Figs. 3 and 4.
ROC analysis revealed significant discriminative power
between responders and non-responders for AP (P<0.001)
Table 2 Pretreatment parameters assessed prior to RE
Parameter Non-responder Responder P-value*
(n=19) (n=11)
Arterial perfusion
(ml/100 ml/min)
12±6 38±15 <0.001
HU on arterial phase CT 52±13 80±24 0.001
HU on portal venous
phase CT**
60±17 82±20 0.07
99mTc-MAA uptake ratio 4.7±5.6 5.0±2.9 0.40
Non-responder according to RECIST 1.1: Stable disease and progressive
disease
Responder according to RECIST 1.1: Partial response and complete
response
*Mann-Whitney U test
**Only where available
Fig. 2 Box plots depicting the arterial perfusion (AP) from perfusion CT
(a), arterial enhancement (aHU, b), portal venous enhancement (pvHU, c)
and 99mTc-MAA uptake ratio determined from SPECT (d), indicating
significantly higher values for AP and aHU for responders as compared to
non-responders. No significant differences were found for pvHU and the
99mTc-MAA uptake ratio.
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with an AUC of 0.971 (95 % CI: 0.918-1.000), as well as for
aHU (P=0.001) with an AUC of 0.866 (95 % CI: 0.730-
1.000). In contrast, pvHU [AUC=0.796 (95 % CI: 0.562-
1.000)] and the 99mTc-MAA uptake ratio [AUC=0.402
(95 % CI: 0.184-0.620] showed no significant discriminative
power (P=0.06 and P =0.38, respectively, Fig. 5).
To compare the specificity of the parameters AP and aHU,
a cutoff value yielding a sensitivity of 91 % for both param-
eters was chosen. This resulted in a cutoff value of >20 ml/
100 ml/min for AP and >55 HU for aHU to determine re-
sponders. The corresponding specificity of 95 % (95 % CI:
75–99 %) for AP was significantly (P=0.003) higher than the
specificity of 53 % (95 % CI: 32–73 %) for aHU.
One-year survival
Patients with an AP>0 ml/100 ml/min showed a significantly
(P=0.01) higher 1-year survival (71.4±17.1 %, median sur-
vival not reached) compared to patients with an AP<0 ml/
100ml/min (27.9±9.7%,median survival 147 days) (Fig. 6a).
Survival of patients with an aHU>55 HU was not significant-
ly different (P=0.12) compared to those with an aHU <55 HU
(Fig. 6b).
The Cox proportional hazard model revealed a hazard ratio
of 0.181 for an AP value>20 ml/100 ml/min for survival
(95 % CI: 0.042-0.786, P=0.02). An aHU >55 HU was not
a significant (P=0.64) predictor of survival when adjusted for
AP. Similarly, the pvHU, 99mTc-MAA uptake ratio, total di-
ameter of all lesions, underlying primary disease, presence of
extrahepatic metastatic disease, total number of liver metasta-
ses, dose applied, and pretreatment with chemotherapy did not
improve the prediction of survival (all P>0.05) when AP was
included in the model.
Discussion
A number of previous studies exist, which employed multi-
phase CT, 99mTc-MAA SPECT and catheter angiography,
analysing the potential relationships between imaging features
and morphologic tumour response and patient survival after
RE of liver metastases [9–12, 30]. For example Sato et al. [10]
evaluated enhancement patterns of liver metastases on arterial
phase CT performed prior to RE, classifying metastases sub-
jectively as hyper- or hypovascular. In their study, authors
could not find a relationship between vascularity and response
to RE. In addition, that study showed that vascularisation was
interpreted differently by different readers and concluded that
quantitative measures for an objective tumour perfusion
Fig. 3 A 66-year-old female patient with metastases from colorectal
cancer in the right liver lobe. The metastasis had an attenuation on portal
venous phase CT (pvHU) of 71 HU (a) and on arterial phase CT (aHU) of
49 HU (b). The arterial perfusion of the metastasis was 25 ml/100 ml/min
(c) and the 99mTc-MAA uptake ratio was 5.8 (d, e). Morphologic follow-
up CT 4 months after RE revealed partial response with a moderate
reduction in metastasis size (f)
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should be considered as opposed to their subjective, semi-
quantitative approach [10].
In our study, measurement of CT attenuation in a
single arterial phase (aHU) was significantly different
between morphologic responders and non-responders to
RE; however, the specificity was low, and prediction of
survival was not possible using the cutoff value from
aHU. This can be explained by the fact that a single-
phase CT may miss peaks in arterial enhancement of
malignancies [31].
Fig. 4 A 73-year-oldmale patient with metastases from colorectal cancer
in both liver lobes. The metastasis had an attenuation on portal venous
phase (pvHU) of 58HU (a) and on arterial phase CT (aHU) of 48 HU (b).
The arterial perfusion of the metastases was 3 ml/100 ml/min (c) and the
99mTc-MAA uptake ratio was 5.2 (d, e). Morphologic follow-up CT
4 months after RE showed progressive disease (f)
Fig. 5 ROC curves for AP, aHU,
pvHU and the 99mTc-MAA
uptake ratio indicating
discriminative power for
distinguishing responders from
non-responders for AP (AUC=
0.971) and aHU (AUC=0.866).
In contrast, pvHU (AUC=0.796)
and the 99mTc-MAA uptake ratio
(AUC=0.402) showed no
significant AUC
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Measurements of portal venous enhancement showed no
discriminative power for differentiating between responders
and non-responders to RE. A recent study by Tochetto et al.
[32] also did not find significant differences in HU values
measured in portal venous phase CT between short-term
responders and non-responders determined by positron emis-
sion tomography. This result can be explained by the fact that
portal venous vascularity represents a minor contributor to the
vascularity of hepatic metastases, which are predominantly
supplied by hepatic arterial flow [33]. Thus, parameters quan-
tifying portal venous attenuation fail to identify responders
from non-responders to an arterially guided therapy such as
RE.
In our study, the 99mTc-MAA uptake ratio did not differ
between responders and non-responders to RE. Our 99mTc-
MAA uptake ratio values with a mean of 5.0 and 4.7 are in line
with those from previous studies [34]. The literature currently
is contradictory regarding the value of 99mTc-MAA scintigra-
phy beyond the evaluation of shunting and dosemisplacement
[1]. A study by Dhabuwala et al. [12] in patients with colo-
rectal liver metastases did not find a predictive value for
99mTc-MAA uptake regarding morphologic tumour response
[12]. Garin et al. [35] calculated the dose deposition based on
99mTc-MAA SPECT and the dose applied in patients with
hepatocellular carcinoma and found that the dose absorbed
by the tumour differed depending on the response to therapy
when using the criteria of the European Association for the
Study of the Liver [36]. Compared to results from our study,
the 99mTc-MAA uptake ratio reported by Garin et al. [35] was
higher in responders and comparable in non-responders. This
indicates differences in the 99mTc-MAA uptake in hepatocel-
lular carcinoma as compared to liver metastases. Further po-
tential reasons for the lack of discriminative power of 99mTc-
MAA SPECT might be the lower spatial resolution of the
technique, the feature of non-time-resolved imaging of the
technique and different pharmacokinetics of the tracer applied
as compared to that from iodinated contrast material.
CT perfusion parameters have previously shown a good
correlation with tumour vascularity determined histopatholog-
ically [37]. Recent studies also demonstrated the ability of CT
perfusion to evaluate therapy response to transarterial
chemoembolisation of hepatocellular carcinoma [38] and to
anti-angiogenic treatment in lung cancer [39]. CT perfusion
can be easily integrated into the clinical routine because of the
high availability of CT, and results from CT perfusion are
known to be reproducible [31, 40, 41]. In our study, quantifi-
cation of arterial perfusion of liver metastases yielded good
sensitivity (91 %) and high specificity (95 %) for predicting
short-term morphologic response and allowed for the discrim-
ination of 1-year survival with RE. In addition, the AP deter-
mined by CT perfusion was the best single, independent
predictor of survival with RE as compared to multiphase CT
and 99mTc-MAA SPECT. This was also true when factors
such as the hepatic tumour load and extrahepatic metastatic
disease were included. This indicates that RE is indeed an
effective treatment method when administered to patients with
a high AP irrespective of underlying primary malignancy or
extension of hepatic metastatic disease.
Some limitations of our study have to be acknowledged.
First, the sample size is relatively small, with heterogeneous
underlying malignancy and colorectal metastasis as the main
malignancy. However, this did not prove to be a statistically
Fig. 6 Kaplan-Meier plots demonstrating a significantly (P=0.010)
higher 1-year survival for patients having a pretreatment AP >20 ml/
100 ml/min (a). In contrast, patients with an aHU>55 HU on pretreat-
ment CT showed no significantly (P=0.123) increased survival (b)
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significant influencing factor. Second, we did not confirm the
predictive value of our findings in another separate patient
population. Therefore, future studies with a larger and more
homogeneous patient population should be performed to val-
idate our initial results. Third, portal venous CT was only
available in a subset of our patients.
In conclusion, our study indicates that the AP of liver
metastases determined by perfusion CT is the best predictor
of morphologic response and 1-year survival with RE com-
pared to the arterial and portal venous CT attenuation and to
the accumulation of 99mTc-MAA particles determined by
SPECT.
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